U.S. markets open in 9 hours 6 minutes

Evelo Biosciences, Inc. (EVLO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6300-0.1200 (-3.20%)
At close: 04:00PM EDT
3.7500 +0.12 (+3.31%)
After hours: 04:47PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close3.7500
Bid3.5500 x 800
Ask3.7500 x 1000
Day's Range3.5613 - 3.8999
52 Week Range0.4800 - 48.4000
Avg. Volume575,082
Market Cap68.371M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-15.1900
Earnings DateNov 13, 2023 - Nov 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EVLO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evelo Biosciences, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    10 months agoMorningstar
View more
  • GlobeNewswire

    Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights

    – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal ax


    Moderna Co-Founder’s Firm Bought Up This Embattled Biotech Stock

    Flagship Pioneering, an investment vehicle helmed by Noubar Afeyan, a co-founder of Moderna and its chairman, bought $12.5 million of shares of biotech Evelo.

  • GlobeNewswire

    Evelo Biosciences Closes $25.5 Million Private Placement

    Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (the “Company” or “Evelo”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private plac